Source: Annual Congress 2001 - COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
J. A. van Noord, J. J. Smeets, S. S. Menjoge, S. Kesten, P. J. G. Cornelissen (Heerlen, Alkmaar, The Netherlands; Ridgefield, United States Of America). Does an acute FEV1 response predict long-term improvements with bronchodilators in patients with COPD?. Eur Respir J 2001; 16: Suppl. 31, 3253

Member's Comments

No comment yet.

Related content which might interest you: Acute bronchodilator response does not predict health outcomes in patients with COPD treated with tiotropium Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009 Clinically important deteriorations in COPD as a measure of response to dual and mono bronchodilator therapy with and without inhaled corticosteroids Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 Evaluation of the individual bronchodilator response in patients with severe COPD Source: Eur Respir J 2002; 20: Suppl. 38, 246s Year: 2002 Assessing bronchodilator response in patients with asthma and COPD using 19F-MRI Source: Virtual Congress 2020 – New imaging techniques applied to old problems Year: 2020 Closing volume predicts the FEV1 response to bronchodilators in patients with COPD Source: Virtual Congress 2020 – Advances in lung function testing Year: 2020 Patterns of bronchodilator reversibility of FEV1 in asthma and COPD patients Source: Annual Congress 2012 - Translational respiratory medicine in asthma and COPD Year: 2012 May the value of FEV1 be helpful in the choice of the antibiotic therapy in acute exacerbation of COPD? Source: Eur Respir J 2001; 18: Suppl. 33, 189s Year: 2001 Do cardiac biomarkers predict long-term outcomes from exacerbations of COPD? Source: International Congress 2017 – Highlights on clinical problems in COPD Year: 2017 Regarding the role of FENO in predicting failure after ICS reduction in mild-to-moderate asthma patients Source: Eur Respir J, 56 (2) 2002375; 10.1183/13993003.02375-2020 Year: 2020 Dual bronchodilation with once-daily QVA149 improves lung function and reduces exacerbations in patients with COPD: The IGNITE trials Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013 Sit-to-stand ability in patients hospitalised for acute exacerbation of COPD: Clinical characteristics and short-term outcomes Source: International Congress 2015 – New insights into exercise and muscle performance Year: 2015 Reducing the decline of FEV1 after a 4-year therapy with montelukast in patients with bronchial asthma Source: Annual Congress 2008 - Recent advances in the pathogenesis and treatment of asthma and COPD Year: 2008 Which lung function variables are the most sensitive to a short bronchodilator in COPD patients? Source: Annual Congress 2008 - Quality spirometry: the only spirometry! Year: 2008 QVA149 improves lung function and reduces exacerbations compared to tiotropium in patients with severe-to-very severe COPD: The SPARK study Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 Does acute bronchodilator test is predictive of inhaled corticosteroid response in COPD/asthma patients? Source: Annual Congress 2010 - Treatment options for asthma Year: 2010 Add-on omalizumab therapy reduces clinically significant and severe asthma exacerbations, and improves FEV1 in patients with severe persistent allergic asthma irrespective of age Source: Eur Respir J 2005; 26: Suppl. 49, 48s Year: 2005 Short-acting bronchodilator reversibility does not predict the response to long-term treatment by indacaterol 150 µg in COPD: REVERBREZ study Source: Annual Congress 2013 –Respiratory and cardiovascular abnormalities in COPD: the role of exercise, nutritional status and inflammation Year: 2013 How the bronchodilatator in COPD patients works Source: Eur Respir J 2004; 24: Suppl. 48, 288s Year: 2004 The bronchodilator response to salmeterol is maintained with regular, long-term use in patients with COPD Source: Eur Respir J 2002; 20: Suppl. 38, 240s Year: 2002 Effect of dupilumab on severe exacerbations in asthma patients with and without lung function improvements Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020